Article info

Download PDFPDF

Extended report
The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial
  1. Correspondence to Dr M Schiff, University of Colorado, 5400 South Monaco Street, Greenwood Village, CO 80111, USA; Lmschiff{at}aol.com
View Full Text

Citation

Schiff M, Pritchard C, Huffstutter JE, et al
The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial

Publication history

  • Accepted November 18, 2008
  • First published December 15, 2008.
Online issue publication 
October 12, 2009

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.